CY1119316T1 - Υδροχλωρικα αλατα μιας αντιβιοτικης ενωσης - Google Patents

Υδροχλωρικα αλατα μιας αντιβιοτικης ενωσης

Info

Publication number
CY1119316T1
CY1119316T1 CY20171100810T CY171100810T CY1119316T1 CY 1119316 T1 CY1119316 T1 CY 1119316T1 CY 20171100810 T CY20171100810 T CY 20171100810T CY 171100810 T CY171100810 T CY 171100810T CY 1119316 T1 CY1119316 T1 CY 1119316T1
Authority
CY
Cyprus
Prior art keywords
antibiotic
union
hydrochloride salts
compounds
relates
Prior art date
Application number
CY20171100810T
Other languages
Greek (el)
English (en)
Inventor
Weijiang Zhang
Ronnie Cheung
Dimitar Filipov
Jack Green
Junning Lee
Original Assignee
Theravance Biopharma Antibiotics Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma Antibiotics Ip, Llc filed Critical Theravance Biopharma Antibiotics Ip, Llc
Publication of CY1119316T1 publication Critical patent/CY1119316T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CY20171100810T 2013-03-13 2017-07-28 Υδροχλωρικα αλατα μιας αντιβιοτικης ενωσης CY1119316T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361779065P 2013-03-13 2013-03-13
PCT/US2014/021064 WO2014158952A1 (en) 2013-03-13 2014-03-06 Hydrochloride salts of an antibiotic compound

Publications (1)

Publication Number Publication Date
CY1119316T1 true CY1119316T1 (el) 2018-02-14

Family

ID=50483481

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100810T CY1119316T1 (el) 2013-03-13 2017-07-28 Υδροχλωρικα αλατα μιας αντιβιοτικης ενωσης

Country Status (32)

Country Link
US (1) US9161990B2 (enExample)
EP (1) EP2968446B1 (enExample)
JP (3) JP6482523B2 (enExample)
KR (1) KR20150126659A (enExample)
CN (1) CN105120883B (enExample)
AR (1) AR095044A1 (enExample)
AU (1) AU2014241481B9 (enExample)
BR (1) BR112015022716A2 (enExample)
CA (1) CA2902720A1 (enExample)
CY (1) CY1119316T1 (enExample)
DK (1) DK2968446T3 (enExample)
EA (1) EA027282B1 (enExample)
ES (1) ES2633964T3 (enExample)
GE (1) GEP20186874B (enExample)
HR (1) HRP20171188T1 (enExample)
HU (1) HUE033738T2 (enExample)
IL (1) IL240663A0 (enExample)
LT (1) LT2968446T (enExample)
MD (1) MD4599C1 (enExample)
ME (1) ME02854B (enExample)
MX (1) MX361984B (enExample)
PH (1) PH12015502060A1 (enExample)
PL (1) PL2968446T3 (enExample)
PT (1) PT2968446T (enExample)
RS (1) RS56141B1 (enExample)
SG (1) SG11201507235YA (enExample)
SI (1) SI2968446T1 (enExample)
SM (1) SMT201700369T1 (enExample)
TW (1) TWI608845B (enExample)
UA (1) UA115086C2 (enExample)
WO (1) WO2014158952A1 (enExample)
ZA (1) ZA201506748B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2980537A1 (en) * 2015-03-24 2016-09-29 Elevance Renewable Sciences, Inc. Polyol esters of metathesized fatty acids and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434287A (en) * 1975-02-20 1984-02-28 Ciba-Geigy Corporation Cephalosporin derivatives
AR229883A1 (es) 1978-05-26 1983-12-30 Glaxo Group Ltd Procedimiento para la preparacion de antibiotico(6r,7r)-7-((z)-2-(2-aminotiazol-4-il)-2-(2-carboxiprop-2-oxiimino)-acetamido)-3-(1-piridinometil)-cef-3-em-4-carboxilato
US4626534A (en) 1984-07-23 1986-12-02 Eli Lilly And Company Pharmaceutical formulation
DE3801179A1 (de) 1988-01-18 1989-07-27 Hoechst Ag Stabilisierung von cephalosporinderivaten durch trocknung mit einem stabilisator sowie stabile zubereitungsformen mit cephalosporinderivaten
JPH0331449A (ja) 1989-06-27 1991-02-12 Yamaha Corp リードフレーム用Fe―Ni合金
DE69004921T2 (de) 1989-09-30 1994-05-05 Eisai Co Ltd Injizierbare Cephalosporinpräparate und ihre Anwendung.
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
JP4142149B2 (ja) 1997-07-10 2008-08-27 明治製菓株式会社 バンコマイシンの凍結乾燥製剤
TWI335332B (en) * 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
PL1618114T3 (pl) * 2003-04-16 2010-12-31 Sandoz Ag Sposoby otrzymywania cefepimy
ATE450540T1 (de) 2003-05-23 2009-12-15 Theravance Inc Quervernetzte glycopeptid-cephalosporin- antibiotika
US6878868B2 (en) 2003-06-24 2005-04-12 Mcmillan Stacy L. Portable high-hat device
US7067482B2 (en) 2003-07-11 2006-06-27 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
TWI342312B (en) 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
EP1656930A1 (en) 2004-11-10 2006-05-17 Basilea Pharmaceutica AG Stabilized freeze-dried formulation for cephalosporin derivatives
US20080103121A1 (en) 2006-10-30 2008-05-01 Gole Dilip J Cephalosporin derivative formulation
FR2932177B1 (fr) 2008-06-06 2012-11-30 Inst Francais Du Petrole Procede d'hydrogenation selective sur un catalyseur contenant de l'or.
JP2010105965A (ja) 2008-10-30 2010-05-13 Taiyo Yakuhin Kogyo Kk バンコマイシン製剤
US8431539B2 (en) 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
US20110124551A1 (en) 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin

Also Published As

Publication number Publication date
WO2014158952A1 (en) 2014-10-02
TWI608845B (zh) 2017-12-21
AU2014241481B2 (en) 2018-02-01
DK2968446T3 (en) 2017-08-28
GEP20186874B (en) 2018-06-25
EP2968446A1 (en) 2016-01-20
IL240663A0 (en) 2015-10-29
ZA201506748B (en) 2017-08-30
AR095044A1 (es) 2015-09-16
MD4599C1 (ro) 2019-06-30
CN105120883A (zh) 2015-12-02
ME02854B (me) 2018-04-20
CA2902720A1 (en) 2014-10-02
MD4599B1 (ro) 2018-11-30
AU2014241481A1 (en) 2015-10-01
MX2015012170A (es) 2015-11-30
MD20150101A2 (ro) 2016-02-29
EA027282B1 (ru) 2017-07-31
TW201444572A (zh) 2014-12-01
JP2018177817A (ja) 2018-11-15
JP6482523B2 (ja) 2019-03-13
AU2014241481B9 (en) 2018-02-15
MX361984B (es) 2018-12-19
LT2968446T (lt) 2017-07-25
UA115086C2 (uk) 2017-09-11
PT2968446T (pt) 2017-07-27
SMT201700369T1 (it) 2017-09-07
HK1214524A1 (en) 2016-07-29
HRP20171188T1 (hr) 2017-10-06
PH12015502060A1 (en) 2016-01-25
US9161990B2 (en) 2015-10-20
SG11201507235YA (en) 2015-10-29
SI2968446T1 (sl) 2017-08-31
JP2016513642A (ja) 2016-05-16
HUE033738T2 (hu) 2018-01-29
KR20150126659A (ko) 2015-11-12
PL2968446T3 (pl) 2017-11-30
US20140274877A1 (en) 2014-09-18
CN105120883B (zh) 2017-11-17
JP2017082016A (ja) 2017-05-18
EA201591697A1 (ru) 2016-02-29
RS56141B1 (sr) 2017-10-31
EP2968446B1 (en) 2017-05-03
ES2633964T3 (es) 2017-09-26
BR112015022716A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
CY1120703T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
CY1122305T1 (el) Ενωσεις υδροξαζολης υδροξαμικου οξεος ως αναστολεις lpxc
CY1121701T1 (el) Οργανικες ενωσεις μονοβακταμης για την αντιμετωπιση βακτηριακων λοιμωξεων
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
MX380092B (es) Tratamiento de la osteoartritis.
BR112018002499A2 (pt) método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica
EA201401292A2 (ru) Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
EA201691085A1 (ru) Замещенные бензамиды и способы их применения
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201790024A1 (ru) Модуляторы toll-подобных рецепторов для лечения вич
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
MX380394B (es) Compuesto novedoso de bifenilo o una sal del mismo.
CL2015001667A1 (es) Derivados de manosa para tratar infecciones bacterianas.
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
EA201690911A1 (ru) Соединения диметилбензойной кислоты
EA201491276A1 (ru) Новые производные бензилсульфонамида, подходящие для применения в качестве ингибиторов mogat-2
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
EA201992370A1 (ru) Соединения и способы для лечения бактериальных инфекций
BR112018074985A2 (pt) composições antibacterianas